Oncotype Dx

From Anvita Health Wiki

Contents 1 Indications 2 Contraindications 3 Specimen 4 Procedure 5 Notes 6 More General Terms 7 References

Indications

• quantifies the likelihood of disease recurrence in women with early-stage breast cancer
• assesses likely benefit from certain types of chemotherapy
• developed for women with early-stage invasive breast cancer who are estrogen receptor positive with negative lymph nodes

Contraindications

• not appropriate for carcinoma in situ
• not appropriate for metastatic cancer

Specimen

• obtained fron tissue removed during the original surgery ( lumpectomy, mastectomy, or core biopsy)
• thin sections of the formalin-fixed, paraffin-embedded tissue are sent to Genomic Health

Procedure

• PCR analysis of a panel of 21 genes obtained from biopsy
• recurrence Score is a number between 0 & 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis

Notes

• introduced in 2004
• price (2010) $4075

More General Terms

• molecular diagnostic test

References

1. Wikipedia: Oncotype DX [1]

Oncotype DX